ArticleJournal of the Royal Statistical Society. Series C, Applied statistics2019
Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times.
Article in Journal of the Royal Statistical Society. Series C, Applied statistics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A Bayesian phase I/II design to determine subgroup-specific optimal dose for immunotherapy sequentially combined with radiotherapy.Pharmaceutical statistics · 2023Trial
- Generalized phase I-II designs to increase long term therapeutic success rate.Pharmaceutical statisticsTrial
- BAR12: Bayesian Autoregressive Phase 1-2 Design for Cell Therapy Trials With Manufacturing Changes.Statistics in medicine · 2026Article
- Bayesian Safety and Futility Monitoring in Phase II Trials Using One Utility-Based Rule.Statistics in medicine · 2024Article
- Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses.Clinical trials (London, England) · 2024Review
- Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Review
- Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity.Biometrics · 2023Article
- Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.International journal of molecular sciences · 2022Review
- Innovative trial design in precision oncology.Seminars in cancer biology · 2022Review
- BIPSE: A biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint.Statistics in medicine · 2022Article
- Article
- Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups.Statistics in medicine · 2021Article
- Adaptive Enrichment Designs in Clinical Trials.Annual review of statistics and its application · 2021Article
- A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes.Bayesian analysis · 2021Article
- Comparison of Phase I-II designs with parametric or semi-parametric models using two different risk-benefit trade-off criteria.Contemporary clinical trials · 2020Article
- A phase I-II design based on periodic and continuous monitoring of disease status and the times to toxicity and death.Statistics in medicine · 2020Article
- BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies.JCO precision oncology · 2020Article
- Review
- Bayesian Utility-Based Designs for Subgroup-Specific Treatment Comparison and Early-Phase Dose Optimization in Oncology Clinical Trials.JCO precision oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A sequentially adaptive Bayesian design is presented for a clinical trial of cord blood derived natural killer cells to treat severe hematologic malignancies. Given six prognostic subgroups defined by disease type and severity, the goal is to optimize cell dose in each subgroup. The trial has five co-primary outcomes, the times to severe toxicity, cytokine release syndrome, disease progression or response, and death. The design assumes a multivariate Weibull regression model, with marginals depending on dose, subgroup, and patient frailties that induce association among the event times. Utilities of all possible combinations of the nonfatal outcomes over the first 100 days following cell infusion are elicited, with posterior mean utility used as a criterion to optimize dose. For each subgroup, the design stops accrual to doses having an unacceptably high death rate, and at the end of the trial selects the optimal safe dose. A simulation study is presented to validate the design's safety, ability to identify optimal doses, and robustness, and to compare it to a simplified design that ignores patient heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.